Cargando…
Tumor innervation and clinical outcome in pancreatic cancer
Pancreatic cancer is a highly aggressive malignancy characterized by poor survival, recurrence after surgery and resistance to therapy. Nerves infiltrate the microenvironment of pancreatic cancers and contribute to tumor progression, however the clinicopathological significance of tumor innervation...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017010/ https://www.ncbi.nlm.nih.gov/pubmed/33795769 http://dx.doi.org/10.1038/s41598-021-86831-w |
_version_ | 1783673976168382464 |
---|---|
author | Ferdoushi, Aysha Griffin, Nathan Marsland, Mark Xu, Xiaoyue Faulkner, Sam Gao, Fangfang Liu, Hui King, Simon J. Denham, James W. van Helden, Dirk F. Jobling, Phillip Jiang, Chen Chen Hondermarck, Hubert |
author_facet | Ferdoushi, Aysha Griffin, Nathan Marsland, Mark Xu, Xiaoyue Faulkner, Sam Gao, Fangfang Liu, Hui King, Simon J. Denham, James W. van Helden, Dirk F. Jobling, Phillip Jiang, Chen Chen Hondermarck, Hubert |
author_sort | Ferdoushi, Aysha |
collection | PubMed |
description | Pancreatic cancer is a highly aggressive malignancy characterized by poor survival, recurrence after surgery and resistance to therapy. Nerves infiltrate the microenvironment of pancreatic cancers and contribute to tumor progression, however the clinicopathological significance of tumor innervation is unclear. In this study, the presence of nerves and their cross-sectional size were quantified by immunohistochemistry for the neuronal markers S-100, PGP9.5 and GAP-43 in a series of 99 pancreatic cancer cases versus 71 normal adjacent pancreatic tissues. A trend was observed between the presence of nerves in the tumor microenvironment of pancreatic cancer and worse overall patient survival (HR = 1.8, 95% CI 0.77–4.28, p = 0.08). The size of nerves, as measured by cross-sectional area, were significantly higher in pancreatic cancer than in the normal adjacent tissue (p = 0.002) and larger nerves were directly associated with worse patient survival (HR = 0.41, 95% CI 0.19–0.87, p = 0.04). In conclusion, this study suggests that the presence and size of nerves within the pancreatic cancer microenvironment are associated with tumor aggressiveness. |
format | Online Article Text |
id | pubmed-8017010 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-80170102021-04-07 Tumor innervation and clinical outcome in pancreatic cancer Ferdoushi, Aysha Griffin, Nathan Marsland, Mark Xu, Xiaoyue Faulkner, Sam Gao, Fangfang Liu, Hui King, Simon J. Denham, James W. van Helden, Dirk F. Jobling, Phillip Jiang, Chen Chen Hondermarck, Hubert Sci Rep Article Pancreatic cancer is a highly aggressive malignancy characterized by poor survival, recurrence after surgery and resistance to therapy. Nerves infiltrate the microenvironment of pancreatic cancers and contribute to tumor progression, however the clinicopathological significance of tumor innervation is unclear. In this study, the presence of nerves and their cross-sectional size were quantified by immunohistochemistry for the neuronal markers S-100, PGP9.5 and GAP-43 in a series of 99 pancreatic cancer cases versus 71 normal adjacent pancreatic tissues. A trend was observed between the presence of nerves in the tumor microenvironment of pancreatic cancer and worse overall patient survival (HR = 1.8, 95% CI 0.77–4.28, p = 0.08). The size of nerves, as measured by cross-sectional area, were significantly higher in pancreatic cancer than in the normal adjacent tissue (p = 0.002) and larger nerves were directly associated with worse patient survival (HR = 0.41, 95% CI 0.19–0.87, p = 0.04). In conclusion, this study suggests that the presence and size of nerves within the pancreatic cancer microenvironment are associated with tumor aggressiveness. Nature Publishing Group UK 2021-04-01 /pmc/articles/PMC8017010/ /pubmed/33795769 http://dx.doi.org/10.1038/s41598-021-86831-w Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Ferdoushi, Aysha Griffin, Nathan Marsland, Mark Xu, Xiaoyue Faulkner, Sam Gao, Fangfang Liu, Hui King, Simon J. Denham, James W. van Helden, Dirk F. Jobling, Phillip Jiang, Chen Chen Hondermarck, Hubert Tumor innervation and clinical outcome in pancreatic cancer |
title | Tumor innervation and clinical outcome in pancreatic cancer |
title_full | Tumor innervation and clinical outcome in pancreatic cancer |
title_fullStr | Tumor innervation and clinical outcome in pancreatic cancer |
title_full_unstemmed | Tumor innervation and clinical outcome in pancreatic cancer |
title_short | Tumor innervation and clinical outcome in pancreatic cancer |
title_sort | tumor innervation and clinical outcome in pancreatic cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017010/ https://www.ncbi.nlm.nih.gov/pubmed/33795769 http://dx.doi.org/10.1038/s41598-021-86831-w |
work_keys_str_mv | AT ferdoushiaysha tumorinnervationandclinicaloutcomeinpancreaticcancer AT griffinnathan tumorinnervationandclinicaloutcomeinpancreaticcancer AT marslandmark tumorinnervationandclinicaloutcomeinpancreaticcancer AT xuxiaoyue tumorinnervationandclinicaloutcomeinpancreaticcancer AT faulknersam tumorinnervationandclinicaloutcomeinpancreaticcancer AT gaofangfang tumorinnervationandclinicaloutcomeinpancreaticcancer AT liuhui tumorinnervationandclinicaloutcomeinpancreaticcancer AT kingsimonj tumorinnervationandclinicaloutcomeinpancreaticcancer AT denhamjamesw tumorinnervationandclinicaloutcomeinpancreaticcancer AT vanheldendirkf tumorinnervationandclinicaloutcomeinpancreaticcancer AT joblingphillip tumorinnervationandclinicaloutcomeinpancreaticcancer AT jiangchenchen tumorinnervationandclinicaloutcomeinpancreaticcancer AT hondermarckhubert tumorinnervationandclinicaloutcomeinpancreaticcancer |